The model provides researchers with key early insights to guide decisions and accelerate drug development
A new study, published in Science Immunology, has revealed that an innovative mouse model developed by genOway, a biotechnology company that provides highly predictive preclinical models and solutions to biopharmaceutical companies, can help scientists better predict the efficacy and safety of therapeutic antibodies in humans.
The model, genO-hFcγR, enables scientists to rank antibody candidates by their likely performance, measure their targeting of specific immune cells, and evaluate their potential to slow disease progression. This provides researchers with key early insights to guide decisions and accelerate drug development.
Due to the species-specific nature of Fcγ receptors, developing this model required multidisciplinary expertise in mouse genetics, antibody biology, and human immunology.
The achievement was made through an international consortium of biopharmaceutical partners, led by genOway, who combined their knowledge to co-develop and co-validate the genO-hFcγR mouse model.
Consortium members included genOway, agenx, Innate Pharma, Vir Biotechnology, and others. The group collaborated with VIB-Ghent University in Belgium, an immunology institute, to publish the study in Science Immunology.
In this study, scientists at VIB-Ghent University mapped Fc receptor expression and regulation to illustrate how the new mouse model could be used to better model human disease and coordinated the publication of the work.
The genO-hFcγR model expands on a previous mouse model developed in 2008 by genOway and its scientific partners, in which several FcγR genes were humanised. Since its launch to the scientific community in 2024, genO-hFcγR has been adopted by biopharmaceutical companies and non-profit organisations, including the Gates Foundation, as part of the foundation’s global health research initiatives.
